Barclays analyst Balaji Prasad raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $200 from $190 and keeps an Overweight rating on the shares post the Q4 report. The firm says the company’s revenues were in line with consensus as Xywav and Epidiolex continue to deliver. The analyst sees Jazz as positioned for revenue growth in 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Optimistic Buy Rating for Jazz Pharmaceuticals Driven by Strategic Cost Management and Positive Market Developments
- Jazz Pharmaceuticals Faces DEI Challenges Amidst Executive Order and Growing Scrutiny
- Jazz downgraded to Neutral at Cantor on oncology strategy ‘head-scratcher’
- Jazz Pharmaceuticals downgraded to Neutral from Overweight at Cantor Fitzgerald
- Jazz Pharmaceuticals price target raised to $205 from $195 at TD Cowen